Nasdaq
$13.04▼ 0.91%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.18BShares out 90.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 3d agoPre-market26.10.22 21:306-KKey event#●●●#●●●#●●●
Alpha Tau Medical Ltd.
Alpha Tau Medical has signed a Memorandum of Understanding (MOU) with Samsung Medical Center (SMC) to explore a potential clinical trial of its Alpha DaRT therapy for pancreatic cancer patients in Korea. This agreement marks the first step toward a potential clinical trial in South Korea, which remains subject to necessary regulatory and ethics committee approvals.…more
$13.04-0.91%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoRegular26.10.19 23:256-KKey event
Alpha Tau Medical Ltd.
Alpha Tau Medical has received FDA approval for an IDE supplement to expand its REGAIN clinical trial for recurrent glioblastoma from 10 to 20 patients. The updated protocol now includes patients with IDH-mutant grade 4 tumors, and the company will present new clinical data at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting from November 12-15.…more
$13.04-0.91%vs prev closeView filingShare - 8.31Pre-market26.08.31 21:006-KKey event
Alpha Tau Medical Ltd.
Alpha Tau Medical has completed patient enrollment for its multicenter IMPACT study of Alpha DaRT for pancreatic cancer, reaching a total of 48 patients. The study, originally planned for 12 patients, was expanded three times due to high demand, and the company is now moving into the follow-up and data maturation phase with initial results targeted for early 2027.…more
$13.04-0.91%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:30#●●●#●●●
Alpha Tau Signs MOU with Samsung Medical Center for Pancreatic Cancer Trial…more
Alpha Tau Medical has signed an MOU with Samsung Medical Center to explore a potential clinical trial for its Alpha DaRT therapy in pancreatic cancer patients. This agreement is in the preliminary stages and remains subject to future regulatory and ethics committee approvals.…more
$13.04-0.91%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 6d agoPre-market26.10.19 21:30
●●●●●●●● ●●●●● ●●●●●●
Alpha Tau Medical has received FDA approval to expand its REGAIN clinical trial for recurrent glioblastoma from 10 to 20 patients. While the expanded study aims to gather data for future regulatory submissions, the therapy remains in the clinical trial phase.…more
$13.04-0.91%vs prev close - 10.5Regular26.10.05 22:45
●●●●●●●● ●●●●● ●●●●●●
Alpha Tau Medical announced that its management will participate in two investor conferences scheduled for October. These events consist of one-on-one meetings and a presentation, which are standard corporate outreach activities.…more
$13.04-0.91%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report